Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 6, 2024
Subject: Regulatory update regarding the Shingrix vaccine in China.
Key Financial Metrics
This filing is a regulatory announcement and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Developments
- Regulatory Acceptance: The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted for review GSK's application for Shingrix (Recombinant Zoster Vaccine) for the prevention of shingles in adults aged 18 and over at increased risk.
- Current Approval Status: Shingrix is already approved in China for adults aged 50 years and over (approved in 2019).
- Target Population Expansion: The new application seeks to expand eligibility to include adults with increased risk factors, such as immunodeficiency, immunosuppression, COPD, diabetes, and asthma.
- Clinical Basis: The application is supported by six clinical trials involving patients aged 18+ with conditions including recent stem cell transplantation, kidney transplant, blood cancer, solid tumors, or HIV.
Outlook, Risks, and Market Context
- Market Opportunity: There are approximately 6 million cases of shingles in China annually. The incidence rate for adults at increased risk is over three times higher than the general population.
- Disease Impact: Shingles affects up to 1 in 3 people globally. Complications include post-herpetic neuralgia (PHN), occurring in 5-30% of cases.
- Risk Factors: GSK includes a standard cautionary statement that forward-looking statements are subject to risks and uncertainties, referencing risk factors detailed in their 2022 Form 20-F and Q4 2023 results.
Investor Verification Checklist
- Verify the timeline for NMPA review completion and potential approval dates for the expanded indication.
- Assess the commercial impact of expanding the eligible population from age 50+ to age 18+ at-risk adults in the Chinese market.
- Review the specific clinical trial data (References 12-17) cited to support the safety and efficacy in immunocompromised populations.
- Monitor for any regulatory feedback or requests for additional data from the NMPA during the review period.